|
|
 |
|
Cancer Faculty
|
 |
 |
|
Charles D. Blanke, MD
|
Martin A. Champagne, MD, FRCP(C)
|
|
|
Joseph M. Connors, MD, FRCPC
|
George D. Demetri, MD, FACP
|
|
|
Maura Dickler, MD
|
Nicholas Donato, PhD
|
|
|
Brian J. Druker, MD
|
Matthew Ellis, MD, PhD
|
|
|
William J. Gradishar, MD
|
Hagop Kantarjian, MD
|
|
|
Barbara Krauser, PhD
|
Amy Langer
|
|
|
Gwen L. Nichols, MD
|
Stephen O'Brien, MBChB, PhD
|
|
|
Oliver Press, MD, PhD
|
Edgardo Rivera, MD
|
|
|
Charles L. Sawyers, MD
|
Charles Schiffer, MD
|
|
|
Kevin M. Shannon, MD
|
Eric Winer, MD
|
|
|
|
|
|
Charles D. Blanke, MD
Dr. Charles Blanke is currently Associate Professor of Medicine in the Division of Hematology/Oncology and Director of the Clinical Gastrointestinal Oncology Program at Oregon Health Sciences University in Portland, Oregon.
Dr. Blanke received his undergraduate and medical degrees from Northwestern University. He completed his internship and residency in Internal Medicine at the Gundersen Medical Foundation in La Crosse, Wisconsin. He then went on and completed a fellowship in Hematology/Oncology at Indiana University. Dr. Blanke is board certified in Internal Medicine and Medical Oncology.
Dr. Blanke has published over 50 medical articles and abstracts in such journals as The New England Journal of Medicine and the Journal of Clinical Oncology. Dr. Blanke has won numerous honors, including the Outstanding Faculty Apple Teaching Award, the American Cancer Society Fellowship, and the American College of Physicians Fellowship. He is a member of the American Society of Clinical Oncology, the American Gastroenterological Association, the American College of Physicians, and the American Medical Association.
Dr. Blanke also sits on the editorial board of the journal Colon & Rectal Cancer: Index and Reviews and is a media consultant for ABC News, the Today Show, and WebMD. His research interests lie in gastrointestinal cancers.
Back to top >>
|
|
|
Martin A. Champagne, MD, FRCP(C)
Dr. Martin Champagne is currently Assistant Professor of Pediatrics at the University of Montreal in Montreal, Canada, and is Director of the Bone Marrow Transplant Program and Blood Bank in the Division of Pediatric Hematology/Oncology. Dr. Champagne is also on staff as a medical oncologist at Sainte-Justine Hospital in Montreal and conducts research in pediatric cancers, including pediatric leukemias.
Dr. Champagne received his medical degree from the University of Sherbrooke and completed his residency in Internal Medicine also at the University of Sherbrooke in Sherbrooke, Quebec, Canada. He completed his fellowship in Hematology at the University of Montreal, his fellowship in Medical Oncology at the University of British Columbia in Vancouver, B.C., and his research fellowship in Pediatric Oncology at Johns Hopkins University.
Back to top >>
|
|
|
Joseph M. Connors, MD, FRCPC
Dr. Joseph M. Connors is a clinical professor at the University of British Columbia in Vancouver and Head of the Lymphoma Tumor Group for the British Columbia Cancer Agency. Before moving to Canada in 1981, Dr. Connors taught at the University of Washington School of Medicine, at Alaska Native Medical Center in Anchorage, and North Carolina Memorial Hospital. A graduate of Yale Medical School, he trained with Dr. Saul Rosenberg at Stanford University and decided to focus his research efforts in understanding lymphoproliferative diseases. Dr. Connors has received grant funding for numerous clinical trials and has published over 100 peer- reviewed scientific articles. He currently serves on LRFA's Honorary Medical Board and is a founding member of Lymphoma Research Foundation Canada. Despite his busy schedule, he sets aside a week every year to teach a high school class on cancer and medicine.
Back to top >>
|
|
|
George D. Demetri, MD, FACP
Dr. George Demetri received his undergraduate degree in Biochemistry from Harvard College and medical degree from Stanford University School of Medicine before completing his Internal Medicine residency and Chief Residency at the University of Washington Hospitals in Seattle. He then completed his Fellowship in Medical Oncology at the Dana-Farber Cancer Institute and Harvard Medical School, where he has served as an Attending Physician since 1989.
Dr. Demetri is the Co-Director of the Center for Sarcoma and Bone Oncology in the Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, MA, and an Assistant Professor of Medicine at the Harvard Medical School. He is a member of several professional societies and editorial boards, as well as the executive medical advisory board for CancerSource.com. Dr. Demetri's research and clinical interests have focused on novel investigational strategies for the management of solid tumors, with a particular emphasis in sarcomas.
Back to top >>
|
|
|
Maura Dickler, MD
Memorial Sloan-Kettering Cancer Center
Back to top >>
|
|
|
Nicholas Donato, PhD
Dr. Nicholas Donato is Associate Professor of Medicine in the Department of Bioimmunotherapy at the M.D. Anderson Cancer Center in Houston, Texas.
Dr. Donato received his B.S. degree in Biochemistry from the University of California, Riverside (1978). He then pursued a Ph.D. in Biochemistry from the College of Natural and Agricultural Sciences at the University of California, Riverside (1984). Following this, Dr. Donato was an NIH Post-doctoral Fellow in the Molecular and Cellular Endocrinology Training Program under Dr. Anthony Norman at UC, Riverside. Then, from 1986 to 1989, he was a Research Associate in the Immunopharmacology Section of the Department of Clinical Immunology and Biological Therapy at the M.D. Anderson Hospital and Tumor Institute.
Dr. Donato has over 33 publications in peer-reviewed journals. He is a member of the American Association for Cancer Research and the American Association for the Advancement of Science. He currently involved in several research projects involving signal transduction and cancer, including "Chemosensitization of NSCLC through signal transduction," "Involvement of tyrosine phosphatases in insulin signaling and apoptosis in breast cancer," and the "Role of Src family kinases in clinical resistance to STI571: Targets for new therapeutic approaches."
Back to top >>
|
|
|
Brian J. Druker, MD
Dr. Brian J. Druker is the Director of the Leukemia Center at Oregon Health Sciences University (OHSU). As a Professor of Medicine, he has joint appointments in the Department of Cell and Developmental Biology and the Department of Biochemistry and Molecular Biology.
Upon graduating from UC San Diego Medical School in 1981, Dr. Druker completed his internship and residency in internal medicine at Barnes Hospital: Washington School of Medicine in St. Louis, Missouri. He then trained in Oncology at Harvard's Dana-Farber Cancer Institute.
After he finished his clinical training, Dr. Druker returned to the lab to begin a research career. He studied the regulation of the growth of cancer cells and began to apply this knowledge to cancer therapies. His work has been instrumental in the development of a drug that has shown remarkable success in the treatment of patients with chronic myeloid leukemia. The clinical trials with STI571, commonly known as Gleevec, have been heralded as a new paradigm in cancer therapy. His role in the development of STI571 and application in the clinic have resulted in numerous awards for Dr. Druker, including the AACR Richard and Hinda Rosenthal Award, the John J. Kenney Award from the Leukemia and Lymphoma Society and the Warren Alpert Prize from Harvard Medical School
Back to top >>
|
|
|
Matthew Ellis, MD, PhD
Duke University Medical Center
Back to top >>
|
|
|
William J. Gradishar, MD
Dr. Gradishar is an Associate Professor of Medicine in the Division of Hematology and Medical Oncology/ Department of Medicine at Northwestern University Medical School and a member of the Robert H. Lurie Comprehensive Cancer Center. Institutionally, he is Director of Breast Medical Oncology and Co-Director of Lynn Sage Breast Program. He is also Program Director of Northwestern University's Hematology/Oncology Fellowship Training Program.
Dr. Gradishar completed his medical school training at the University of Illinois Abraham School of Medicine. He completed a residency and chief residency in Internal Medicine at Michael Reese Hospital and Medical Center in Chicago. A fellowship in Medical Oncology was completed at the University of Chicago in 1990. He is a Diplomat of the American Board of Internal Medicine in both Internal Medicine and Medical Oncology.
Dr. Gradishar is a member of several professional organizations including the American College of Physicians (Fellow), American Association for Cancer Research, American Federation for Clinical Research, Association of Subspecialty Professors, and the American Society of Breast Disease. He is a member of the Publication Committee and the Oncology Training Program Committee of the American Society of Clinical Oncology (ASCO). He also serves as Vice Chair of the ASCO Communication Committee.
Dr. Gradishar is a member of the Breast Cancer Core Committee of the Eastern Cooperative Oncology Group. He is a member of several expert panels including the National Comprehensive Cancer Network (NCCN) Breast Cancer Practice Guideline Committee and the NCCN Breast Cancer Prevention Committee. He has served on the ASCO Chemoprotectant Expert Panel. He has been a member of several study sections including: Susan G. Komen Breast Cancer Foundation, the Committee on Cell Structure and Metastases of the American Cancer Society, Cell Biology Committee of the American Cancer Society, Department of Defense Breast Cancer Research Program (1. Epidemiology; 2. Clinical and Experimental Therapeutics), NIH National Action Plan on Breast Cancer. He currently has finding through the Department of Defense to evaluate the efficacy of Networked Breast Cancer Conferences as a means of increasing access to clinical trials.
Dr. Gradishar is a reviewer for numerous journals including the Journal of the National Cancer Institute, Journal of Clinical Oncology and Clinical Cancer Research. He has published in the area of breast cancer therapeutics with a focus on new endocrine therapy and chemotherapy. His research interest focuses on the development of novel therapeutics for the treatment of breast cancer.
Back to top >>
|
|
|
Hagop Kantarjian, MD
Dr. Hagop Kantarjian is currently Chairman of the Leukemia Department, Professor of Medicine, and Internist at M.D. Anderson Cancer Center in Houston, Texas. He received his medical degree from the American University of Beirut and completed his fellowship in the Department of Developmental Therapeutics at MD Anderson Cancer Center. He became Chairman of the Leukemia Department in 1995 and is Board Certified in Internal Medicine, Medical Oncology, and Hematology.
Dr. Kantarjian now specializes in chronic myeloid leukemia and acute lymphocytic leukemia, and is interested in creating new treatment approaches for these diseases. He has participated in numerous editorial boards and medical societies and holding administrative positions. Dr. Kantarjian has also authored and contributed to over 560 medical publications and abstracts in such journals as the Journal of Clinical Oncology and the New England Journal of Medicine. For his achievements, Dr. Kantarjian has received numerous awards, including a Leukemia Society of America Scholarship from 1989-94 and a Leukemia Society of America Special Fellow from 1982-1983.
Back to top >>
|
|
|
Barbara Krauser, PhD
SHARE- Self-help for Women with Breast or Ovarian Cancer
Back to top >>
|
|
|
Amy Langer
Executive Director, National Alliance of Breast Cancer Organizations
Back to top >>
|
|
|
Gwen L. Nichols, MD
Dr. Nichols is the Aboodi Assistant Professor of Medicine, and director of the hematologic malignancies program at Columbia University College of Physicians and Surgeons, Herbert Irving Comprehensive Cancer Center. Dr. Nichols has an active practice specializing in treatment of leukemia and lymphoma. She is the principal investigator for a variety of clinical trials in treatment of hematologic malignancies including new drug treatments, antibodies and vaccines, and new techniques for stem cell transplantation. Her laboratory efforts are focused on understanding secondary leukemia risks and signal transduction in leukemias.
Back to top >>
|
|
|
Stephen O'Brien, MBChB, PhD
Dr. Stephen O'Brien is a Senior Lecturer at the University of Newcastle and Consultant Haematologist at the Royal Victoria Infirmary, Newcastle, UK. Following graduation and internal medical experience in Manchester, his training in haematology was undertaken at the Hammersmith Hospital in London where he subsequently completed a PhD under the direction of Prof. John Goldman.
He treated the first UK patients to receive STI571 in September 1999 in Newcastle and continues to be closely involved with ongoing trials with this agent. His principal research interests are in the biology and therapy of CML. He has been involved in the laboratory and clinical development of novel therapies for CML for a number of years including international autografting studies and pilot studies with antisense oligonucleotides. He is the principal investigator for the first study combining STI571 with interferon (PISCES) and is interested in the clinical development of novel signal transduction inhibitors. He is a member of the UK Medical Research Council Leukaemia Trials group and is involved with collaborations with a number of international cooperative trial groups conducting independent phase III trials with STI571.
Back to top >>
|
|
|
Oliver Press, MD, PhD
Fred Hutchinson Cancer Center, Seattle, Washington
Back to top >>
|
|
|
Edgardo Rivera, MD
M. D. Anderson Cancer Center
Back to top >>
|
|
|
Charles L. Sawyers, MD
Dr. Charles Sawyers is currently Professor of Medicine, Division of Hematology/Oncology at UCLA School of Medicine and Director of the Prostate Cancer Program area at the UCLA Jonsson Cancer Center in Los Angeles, California.
Dr. Sawyers received his undergraduate degree from Princeton University and his medical degree from the Johns Hopkins School of Medicine. He completed a residency in Internal Medicine at the UCSF Medical Center, and a clinical fellowship in Hematology/Oncology at the UCLA School of Medicine. He also completed a post-doctoral fellowship in Molecular Biology at the UCLA School of Medicine. Dr. Sawyers is board certified in Internal Medicine, Medical Oncology, and Hematology.
Dr. Sawyers has published over 30 scientific and medical papers in such journals as the New England Journal of Medicine and Cell. He has won numerous honors and awards, including the Franklin D. Murphy Prize, Stohlman Scholar of the Leukemia and Lymphoma Society, and he was recently appointed the Peter Bing Professor at the UCLA School of Medicine.
Dr. Sawyers research interests include signal transduction and cell growth in such diseases as leukemia and prostate cancer.
Back to top >>
|
|
|
Charles Schiffer, MD
Dr. Charles Schiffer is currently Professor of Medicine and Oncology at the Karmanos Cancer Institute at Wayne State University School of Medicine in Detroit, Michigan.
Dr. Schiffer received his undergraduate degree from Brandeis University and his medical degree from New York University School of Medicine. He stayed on at NYU, completing his internship and residency in Internal Medicine at Bellevue Hospital, where he was Chief Resident. Dr. Schiffer is board certified in Internal Medicine and Medical Oncology. Before assuming his current position at Wayne State University School of Medicine, Dr. Schiffer was Chief of the Division of Hematology at the University of Maryland School of Medicine, and also spent several years as Head of the Cell Component Therapy Section at the Baltimore Cancer Research Program. He has served as Chair of the Leukemia Committee of the Cancer and Leukemia Group B and of the Oncology Drug Advisory Committee on the FDA.
Dr. Schiffer is a member of numerous professional societies including the American Society of Hematology and the American Society of Clinical Oncology, and sits on the editorial boards of several oncology journals, and is the editor of the Leukemia section in the journal Current Opinion in Oncology. Dr. Schiffer is a respected expert in leukemia and platelet transfusion therapy and has published numerous papers on these subjects. He has been consistently named among the best doctors in America for the treatment of leukemia, for the past ten years.
Back to top >>
|
|
|
Kevin M. Shannon, MD
Dr. Kevin Shannon is currently Professor of Pediatrics at the University of California, San Francisco School of Medicine and Program Leader of the Hematopoietic Malignancies Program at the UCSF Cancer Center.
Dr. Shannon received his undergraduate degree from Williams College and his medical degree from Cornell University Medical College. He then went on and completed his residency in Pediatrics at the University of Texas Southwestern in Dallas, Texas and his fellowship in Hematology/Oncology at the University of California, San Francisco.
Dr. Shannon is board certified in Pediatrics and Hematology/Oncology and sits on numerous scientific boards including the Subcommittee on Pediatric Hematology of the American Society of Hematology and the scientific advisory boards of the Fanconi Anemia Research Fund, National Neurofibromatosis Foundation, and the Concern Foundation for Cancer Research.
Dr. Shannon has published over 55 scientific papers in such journals as the New England Journal of Medicine, Blood, and the Proceedings of the National Academy of Sciences, and has received numerous awards including the American Academy of Pediatrics Award for Excellence in Pediatric Research. Dr. Shannon was recently appointed the Roma and Marvin Auerback Distinguished Professor of Molecular Oncology.
Back to top >>
|
|
|
Eric Winer, MD
Dana Farber Cancer Institute
Back to top >>
|
|
|
|
|
Current Developments In 
